Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
1.
Nefrología (Madr.) ; 36(6): 653-659, nov.-dic. 2016. tab, graf
Article in English | IBECS | ID: ibc-158755

ABSTRACT

Objetivo: Evaluar la insuficiencia renal en pacientes con diabetes tipo 2 con normoalbuminuria o microalbuminuria mediante la detección de la concentración de cistatina C en suero y de TGF-β en suero y orina. Métodos: Estudio transversal realizado en el Departamento de Endocrinología de la Facultad de Medicina de la Universidad de Baskent. En el estudio, se incluyó a pacientes con diabetes mellitus tipo 2 sin nefropatía diabética manifiesta conocida. Los pacientes seleccionados se estratificaron en 4 grupos, agrupados en términos de edad, sexo, grado de microalbuminuria y filtración glomerular estimada (FGe) calculada mediante la fórmula MDRD. Resultados: Se incluyó a 78 pacientes. Se clasificaron en 4 grupos dependiendo de la excreción urinaria de albúmina y de la FGe. Se observó que la complicación macrovascular era mayor en los pacientes con microalbuminuria que en otros (p<0,01), pero no hubo diferencias con relación a otras complicaciones diabéticas. La concentración sérica de cistatina C fue significativamente mayor en los pacientes del grupo 1 con normoalbuminuria, mientras que las concentraciones de TGF-β1 en suero y orina fueron mayores en los pacientes del grupo 2 con microalbuminuria. Se observó una correlación negativa entre la concentración sérica de cistatina C y la FGe en los pacientes del grupo 2 (r=−0,892, p<0,001). Por último, se observó una correlación negativa entre la FGe y la cistatina C en todos los grupos de pacientes (r=−0,726, p=0,001). Conclusiones: Aunque se recomienda la excreción urinaria de albúmina para la detección de la nefropatía diabética tipo 2, hay un grupo de pacientes con disminución de la FGe, pero sin aumento de la excreción urinaria de albúmina, en los que estaba indicado usar la concentración de cistatina C en suero como un biomarcador temprano de nefropatía diabética (AU)


Objective: To evaluate renal impairment in type 2 diabetic patients with normoalbuminuria or microalbuminuria by detection of serum cystatin C and serum and urinary TGF-β levels. Methods: Cross-sectional study conducted at the Department of Endocrinology in Baskent University School of Medicine. Patients with type 2 diabetes mellitus without known overt diabetic nephropathy were included in the study. Recruited patients were stratified into four groups, matched in terms of age, gender, microalbuminuria level and estimated GFR calculated with MDRD. Results: 78 patients were enrolled. They were categorized into four groups depending on their urinary albumin excretion and estimated glomerular filtration rate. Macrovascular complication was found to be higher in patients with microalbuminuria than in other patients (p<0.01), but there were no differences in terms of other diabetic complications. Serum cystatin C level was significantly higher in normoalbuminuric group one patients, while serum and urinary TGF-β1 levels were higher in microalbuminuric group two patients. The serum level of cystatin C was found to negatively correlate with eGFR in group two patients (r=−0.892, p<0.001). Finally, there was a negative correlation between eGFR and cystatin C in all the patient groups (r=−0.726, p=0.001). Conclusions: Although urinary albumin excretion is recommended for the detection of type two diabetic nephropathy, there is a group of patients with decreased eGFR but without increased urinary albumin excretion, in which serum cystatin C level was indicated to be used as an early biomarker of diabetic nephropathy (AU)


Subject(s)
Humans , Diabetic Nephropathies/physiopathology , Cystatin C/analysis , Transforming Growth Factor beta/analysis , Biomarkers/analysis , Albuminuria/diagnosis , Glomerular Filtration Rate
2.
Nefrologia ; 36(6): 653-659, 2016.
Article in English, Spanish | MEDLINE | ID: mdl-27745866

ABSTRACT

OBJECTIVE: To evaluate renal impairment in type 2 diabetic patients with normoalbuminuria or microalbuminuria by detection of serum cystatin C and serum and urinary TGF-ß levels. METHODS: Cross-sectional study conducted at the Department of Endocrinology in Baskent University School of Medicine. Patients with type 2 diabetes mellitus without known overt diabetic nephropathy were included in the study. Recruited patients were stratified into four groups, matched in terms of age, gender, microalbuminuria level and estimated GFR calculated with MDRD. RESULTS: 78 patients were enrolled. They were categorized into four groups depending on their urinary albumin excretion and estimated glomerular filtration rate. Macrovascular complication was found to be higher in patients with microalbuminuria than in other patients (p<0.01), but there were no differences in terms of other diabetic complications. Serum cystatin C level was significantly higher in normoalbuminuric group one patients, while serum and urinary TGF-ß1 levels were higher in microalbuminuric group two patients. The serum level of cystatin C was found to negatively correlate with eGFR in group two patients (r=-0.892, p<0.001). Finally, there was a negative correlation between eGFR and cystatin C in all the patient groups (r=-0.726, p=0.001). CONCLUSIONS: Although urinary albumin excretion is recommended for the detection of type two diabetic nephropathy, there is a group of patients with decreased eGFR but without increased urinary albumin excretion, in which serum cystatin C level was indicated to be used as an early biomarker of diabetic nephropathy.


Subject(s)
Cystatin C/blood , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/blood , Transforming Growth Factor beta/blood , Adult , Aged , Albuminuria/blood , Biomarkers/blood , Cross-Sectional Studies , Diabetes Mellitus, Type 2/blood , Female , Glomerular Filtration Rate , Humans , Male , Middle Aged
3.
Pak J Med Sci ; 31(1): 19-24, 2015.
Article in English | MEDLINE | ID: mdl-25878608

ABSTRACT

OBJECTIVE: Diabetes is a multifactorial disorder posing a great challenge to public health. In this study, we aimed to evaluate the relationship between depression, coping strategies, glycemic control and patient compliance in type 2 diabetic patients. METHODS: Total 110 outpatients (mean (SD) age: 57.9 years (10.5), 56.4% were females) with type 2 diabetes mellitus were included in this descriptive and cross-sectional study. They were followed-up in the endocrinology outpatient clinic at Baskent University Istanbul Hospital Turkey. A questionnaire including items on sociodemographics, patient compliance, Beck Depression Inventory (BDI) and Ways of Coping Questionnaire (WCQ) were used. Glycemic control was measured by HbA1c levels. RESULTS: Mean depression score was 12.6(9.2) with moderate to severe depression in 30.9% of study participants. Overall scores for BDI, fatalism and helplessness approaches were significantly higher among females compared with male patients. Depression scores were correlated positively to duration of disease (r=0.190, p=0.047), fatalistic (r=0.247, p=0.009), helplessness (r=0.543, p=0.000) and avoidance (r=0.261, p=0.006) approaches, and negatively to educational status (r=-0.311, p=0.001) and problem solving-optimistic approach (r=-0.381, p=0.000). CONCLUSIONS: Likelihood of depression was frequent, consistent with literature and was associated with gender, educational status, coping strategies, duration of diabetes and patient compliance with treatment in our study. Screening for depression and patient education may improve the quality of life in diabetic patients.

4.
Cent Eur J Immunol ; 39(4): 493-7, 2014.
Article in English | MEDLINE | ID: mdl-26155169

ABSTRACT

INTRODUCTION: It has been known that vitamin D has some immunomodulatory effects and in autoimmune thyroid diseases, vitamin D deficiency was more prevalent. In this study, our aim was to investigate the relationship between thyroid autoantibodies and vitamin D. MATERIAL AND METHODS: Group 1 and 2 consisted of 254 and 27 newly diagnosed Hashimoto's thyroiditis (HT) and Graves' disease (GD) cases, respectively; age-matched 124 healthy subjects were enrolled as controls (group 3). All subjects (n = 405) were evaluated for 25OHD and thyroid autoantibody [anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-tg)] levels. RESULTS: Group 2 and group 1 patients had lower 25OHD levels than group 3 subjects 14.9 ±8.6 ng/ml, 19.4 ±10.1 ng/ml and 22.5 ±15.4 ng/ml, respectively (p < 0.001). Serum 25OHD levels inversely correlated with anti-tg (r = -0.136, p = 0.025), anti-TPO (r = -0.176, p = 0.003) and parathormone (PTH) (r = -0.240, p < 0.001). Group 2 patients had higher anti-tg and anti-TPO levels than group 1 and 3 (p < 0.001). CONCLUSIONS: In this study, we found that patients with autoimmune thyroid disease (AITD) present with lower vitamin D levels and GD patients have higher prevalence. Since we found an inverse correlation between vitamin D levels and thyroid antibody levels, we may suggest that vitamin D deficiency is one of the potential factors in pathogenesis of autoimmune thyroid disorders.

5.
Acta Diabetol ; 49 Suppl 1: S115-22, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22101910

ABSTRACT

Rosiglitazone often results in weight gain. We hypothesized that rosiglitazone may modulate circulating levels of ghrelin and peptide YY(3-36) and this modulation may be related to weight-gaining effect of this agent. This study was designed as an open-label, randomized, controlled trial of 3-month duration. Women with newly diagnosed type 2 diabetes were studied. Twenty-eight of the 55 eligible participants were randomly assigned to receive rosiglitazone (4 mg/d). Twenty-seven patients with diabetes matched for age and body mass index served as controls on diet alone. We evaluated the effects of 3 months of rosiglitazone treatment on fasting peptide YY(3-36) and ghrelin levels, and anthropometric measurements. The 3-month administration of rosiglitazone reduced fasting plasma peptide YY(3-36) levels by 25%, the between-group difference was statistically significant. No effect of this thiazolidinedione compound on fasting ghrelin concentrations was observed at the end of study. The ghrelin/body mass index ratio also did not change significantly after treatment. Seventy-five percent of the women with diabetes complained of increased hunger at the end of study. Nevertheless, all subjects exhibited a decrease in fasting PYY levels after 3 months of rosiglitazone therapy, irrespective of the levels of hunger. There was no significant correlation between changes in peptide YY(3-36) and those in anthropometric parameters and insulin sensitivity at the end of the study. Rosiglitazone-induced decrease in fasting peptide YY(3-36) levels may in part contribute to orexigenic and weight-gaining effect of this thiazolidinedione derivative.


Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Peptide YY/blood , Thiazolidinediones/therapeutic use , Weight Gain/drug effects , Adult , Aged , Diabetes Mellitus, Type 2/physiopathology , Down-Regulation/drug effects , Fasting/blood , Female , Humans , Middle Aged , Rosiglitazone , Thiazolidinediones/adverse effects
6.
Endocrine ; 37(2): 294-300, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20960266

ABSTRACT

Insulin resistance, which provides a convenient milieu for platelet activation, has been closely associated with atherosclerotic disorders. Although it often accompanies hyperprolactinemia, findings conflict concerning its clinical impact in macroprolactinemia. In order to investigate the relationship between hyperprolactinemia and platelet activation evidenced by ADP-stimulated P-selectin expression on flow cytometry, we studied hyperprolactinemic, macroprolactinemic, and normoprolactinemic subjects. Thirty-four hyperprolactinemic and 44 age- and body mass index-matched euprolactinemic premenopausal women were included. They were matched regarding insulin sensitivity status, waist circumference, blood pressures, and plasma lipids. In order to detect macroprolactinemia among hyperprolactinemic cases, prolactin was measured before and after polyethylene glycol (PEG) precipitation in patients' sera. P-selectin expression was significantly higher in the hyperprolactinemic group (P =0.001), and 41.2% of them exhibited macroprolactinemia. Expression of P-selectin was comparable between the macroprolactin-negative (monomeric hyperprolactinemia; n = 20) and -positive (n = 14) subgroups (P = 0.90). Both subgroups showed greater expression compared with normoprolactinemic controls (P = 0.014 and 0.005, respectively). Platelet activation accompanies the atherosclerotic disorders closely associated with insulin resistance. Among groups matched with regard to insulin-sensitivity markers, both monomeric hyperprolactinemia and macroprolactinemia appeared to promote platelet activation.


Subject(s)
Hyperprolactinemia/blood , Platelet Activation/physiology , Prolactinoma/blood , Adult , Biomarkers/blood , Female , Flow Cytometry , Humans , Hyperprolactinemia/epidemiology , Insulin Resistance/physiology , Metabolic Syndrome/blood , Metabolic Syndrome/epidemiology , P-Selectin/metabolism , Prolactin/blood , Prolactinoma/epidemiology , Risk Factors , Young Adult
7.
Fertil Steril ; 93(4): 1227-33, 2010 Mar 01.
Article in English | MEDLINE | ID: mdl-19108830

ABSTRACT

OBJECTIVE: To evaluate the plasma asymmetric dimethyl arginine (ADMA) levels and carotid intima-media thickness (IMT) in patients with polycystic ovary syndrome (PCOS). DESIGN: Prospective study. SETTING: University medical center. PATIENT(S): Thirty-five patients with PCOS and 31 healthy controls. INTERVENTION(S): Peripheral venous puncture, ultrasonography, oral glucose tolerance test (OGTT). MAIN OUTCOME MEASURE(S): Plasma ADMA, serum FSH, LH, dehydroepiandrosterone sulfate (DHEAS), free T and total T, insulin, fasting plasma glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglyceride, homocysteine, fibrinogen, C-reactive protein, and carotid IMT. RESULT(S): The PCOS group had higher levels of androgens, triglycerides, homocysteine, insulin, and homeostasis model assessment of insulin resistance when compared with controls. There were no significant differences in ADMA levels and IMT between the two groups. The fasting plasma glucose, total cholesterol, HDL cholesterol, LDL cholesterol, fibrinogen, and C-reactive protein levels were not different among the groups. Intima-media thickness was significantly correlated with DHEAS, but there was no association between IMT and ADMA. CONCLUSION(S): Results of our study revealed that ADMA levels and carotid IMT in patients with PCOS are not different from healthy controls.


Subject(s)
Arginine/analogs & derivatives , Obesity/blood , Polycystic Ovary Syndrome/blood , Tunica Intima/diagnostic imaging , Tunica Media/diagnostic imaging , Adolescent , Adult , Arginine/blood , Energy Metabolism/physiology , Female , Humans , Obesity/diagnostic imaging , Obesity/metabolism , Polycystic Ovary Syndrome/diagnostic imaging , Polycystic Ovary Syndrome/metabolism , Prospective Studies , Ultrasonography , Young Adult
8.
Med Princ Pract ; 18(6): 482-5, 2009.
Article in English | MEDLINE | ID: mdl-19797926

ABSTRACT

OBJECTIVE: We report a rare case of 49,XXXXY syndrome with autoimmune diabetes (requiring insulin therapy), bilateral cataracts and unilateral glaucoma. CLINICAL PRESENTATION AND INTERVENTION: A 25-year-old man with mental retardation presented with multiple skeletal abnormalities, polyuria and polydipsia. He had high glucose concentrations, without ketonuria, and hypergonadotropic hypogonadism. Ophthalmic examination revealed a polar cataract in both eyes and increased intraocular pressure in the left eye. The anti-islet cell antibody test was positive, and anti-glutamic acid decarboxylase autoantibody levels were elevated. Karyotype analysis revealed 49,XXXXY. Intensive insulin therapy and testosterone replacements were started. CONCLUSION: The autoimmune nature of diabetes that we observed in our patient seems to be predisposed by hypogonadism. Cataract and glaucoma in this case seem to be the result of diabetes, and an association of these ocular manifestations with the syndrome 49,XXXXY seems unlikely.


Subject(s)
Diabetes Mellitus, Type 1/complications , Intellectual Disability/complications , Klinefelter Syndrome/complications , Adult , Cataract/etiology , Diabetes Mellitus, Type 1/diagnosis , Diabetes Mellitus, Type 1/drug therapy , Glaucoma/etiology , Hormone Replacement Therapy , Humans , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Karyotyping , Klinefelter Syndrome/drug therapy , Male , Testosterone/therapeutic use
9.
J Natl Med Assoc ; 100(6): 716-9, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18595575

ABSTRACT

OBJECTIVE: Amiodarone-induced thyrotoxicosis (AIT) is usually classified into two types: type 1, in which a high iodine content triggers the autonomous production of thyroid hormone; and type 2, in which destructive thyroiditis causes the release of preformed thyroid hormone. AIT is a difficult management problem that sometimes requires ablative thyroid therapy. The use of radioactive iodine (RAI) therapy in patients with type-1 AIT who had a 24-hour radioactive iodine uptake (RAIU) value of >10% has been previously reported. Despite its documented efficacy at usual doses (10-30 mCi) in patients with type-1 AIT, the efficacy of RAI in those with type-2 AIT has never been questioned, because type-2 patients usually have low RAIU. We thought that high adjusted-dose RAI might be an attractive alternative to thyroid gland ablation in patients with type-2 AIT. PATIENTS AND METHODS: Four patients with type-2 AIT who required thyroid ablation were included in the study. These individuals were either poor candidates for surgery or had refused surgery. The size of the thyroid gland in all subjects was within normal limits, and each thyroid was characterized by a homogenous echotexture on ultrasonography, the absence of vascularity on Doppler sonography, a low (<4%) 24-hour RAIU value and the absence of thyroid autoantibodies-all of which are characteristic of type-2 AIT. RESULTS: The patients were initially treated with thionamides and glucocorticoids. All patients except one achieved euthyroidism before RAI therapy. All four patients received one dose of RAI (range 29-80 mCi) and followed up for 12 months. No exacerbation of thyrotoxicosis was noted after RAI therapy. Hypothyroidism (in three patients) or euthyroidism (in one patient) was achieved in first six months. CONCLUSIONS: In patients with type-2 AIT, RAI treatment may be the therapy of choice for thyroid gland ablation.


Subject(s)
Amiodarone/adverse effects , Anti-Arrhythmia Agents/adverse effects , Iodine Radioisotopes/administration & dosage , Thyrotoxicosis/chemically induced , Thyrotoxicosis/radiotherapy , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Thyrotoxicosis/diagnosis , Treatment Outcome
10.
J Natl Med Assoc ; 100(4): 401-5, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18481478

ABSTRACT

BACKGROUND: Brain natriuretic peptide (BNP) is secreted from the ventricular myocardium in response to volume expansion and pressure overload. Serum BNP levels are also affected by thyroid function status, which was mostly related to a direct stimulatory effect of thyroid hormones on the secretion of BNP. Although the diagnostic value of BNP in heart failure is undisputed, its value in the presence of the thyroid dysfunction has been recently questioned. The aim of this study was to evaluate the influence of thyroid dysfunction on BNP levels. METHODS: Evaluation of 18 overt and 47 subclinical hyperthyroid patients together with 39 subclinical and 13 overt hypothyroid patients was carried out in a cross-sectional study. Thirty-three age-, sex- and body mass index (BMI)-matched control subjects were also included. RESULTS: BNP levels were more than five times higher in hyperthyroid than euthyroid control subjects (P < 0.001). BNP levels were also higher in subclinical hyperthyroidism than euthyroid control subjects (P = 0.09). Correlation analysis revealed that free T4 and free T3 concentrations were associated with high serum BNP levels. The BNP level in patients with subclinical or overt hypothyroidism was similar to that of the controls. CONCLUSION: The current study provides additional insight into the diagnostic value of BNP in the presence of coexistent thyroid dysfunction and demonstrates important independent effects of thyroid hormones upon BNP plasma concentrations.


Subject(s)
Heart Failure/diagnosis , Heart Failure/etiology , Hyperthyroidism/complications , Hyperthyroidism/diagnosis , Hypothyroidism/diagnosis , Natriuretic Peptide, Brain/blood , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Cross-Sectional Studies , Female , Heart Ventricles , Humans , Hyperthyroidism/blood , Hypothyroidism/blood , Male , Middle Aged , Myocardium/metabolism , Natriuretic Peptide, Brain/metabolism , Prospective Studies , Thyroid Hormones/physiology
11.
Neuro Endocrinol Lett ; 28(6): 727-33, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18063933

ABSTRACT

OBJECTIVE: To evaluate the short-term effects of Lanreotide Autogel on insulin sensitivity markers among acromegalic patients with pituitary tumors. DESIGN: Prospective clinical trial with six months of follow-up. SETTING: A tertiary endocrinology clinic. MATERIALS AND METHODS: Naïve patients (patient No. 1 and patient No. 3) and patients who experienced prior somatostatin analogue treatment (patient No. 2, patient No. 4, and patient No. 5) were included. Before and after 6 months of Lanreotide Autogel therapy, insulin sensitivity in each subject was determined using homeostasis model assessment of insulin resistance and beta-cell function formula. Euglycemic hyperinsulinemic clamp test was also performed to evaluate whole insulin sensitivity and was indicated as an 'M' index. RESULTS: All patients experienced reduction in their HOMA-beta. We noted major HOMA-beta decreases accompanied by pronounced increases in M indices for patients Nos. 1, 2 and 3 (1.03 vs. 8.22, 2.98 vs. 4.70, and 5.09 vs. 13.09, respectively). The increases in M indices of these patients were with marked decreases in GH levels (34.20 vs. 15.30 microg/l, 4.25 vs. 0.74 and 5.0 vs. 0.66 ng/mL, respectively). Minor decline in HOMA-beta and worsened M index and almost stable GH were observed in patients Nos. 4 and 5. Except for patient No. 3, all participants showed declining HOMA-IR. CONCLUSIONS: Short-term Lanreotide Autogel treatment has been observed to improve M indices of acromegalic patients whose GH levels exhibited marked reduction. This amelioration seemed to be related to decreases in GH levels rather than to a direct drug effect.


Subject(s)
Acromegaly/drug therapy , Antineoplastic Agents/therapeutic use , Peptides, Cyclic/therapeutic use , Pituitary Neoplasms/drug therapy , Somatostatin/analogs & derivatives , Acromegaly/etiology , Acromegaly/metabolism , Adult , Antineoplastic Agents/administration & dosage , Blood Glucose/metabolism , Delayed-Action Preparations , Drug Administration Schedule , Female , Follow-Up Studies , Homeostasis/drug effects , Human Growth Hormone/blood , Humans , Insulin/metabolism , Insulin Resistance , Insulin-Like Growth Factor I/analysis , Insulin-Secreting Cells/drug effects , Male , Middle Aged , Peptides, Cyclic/administration & dosage , Pituitary Neoplasms/complications , Pituitary Neoplasms/surgery , Prospective Studies , Somatostatin/administration & dosage , Somatostatin/therapeutic use
12.
Asia Pac J Clin Nutr ; 16(3): 443-7, 2007.
Article in English | MEDLINE | ID: mdl-17704025

ABSTRACT

Our aim was to determine the relationship between body fat percentage (BF%) and body mass index (BMI) and to evaluate the validity of World Health Organisation's BMI cut-off values for obesity. Adult out-patients (n=909, 249 men, 660 women), mean age; 40.5 +/- 14.1 years were included. According to WHO's BMI criteria, 440 subjects were obese (79 men, 361 women). The BF% of participants were measured using a bioelectrical impedance analysis (BIA) system (TANITA). Randomly selected 30 patients were also subjected to the dual-energy X-ray absorptiometry (DEXA) procedure for evaluation of the validity of TANITA measurements. The BF% results obtained by DEXA and TANITA revealed good correlation (r =0.952, p= 0.382). There was a positive correlation between BF% and BMI (p<0.001) for both methods. Cut-off values for BMI were calculated as 28.0 kg/m2 for women, 28.2 kg/m2 for men, if obesity was defined as BF >= 25% in men, >= 35% in women according to WHOfs criteria. Using the new cut-off values, the frequency of obesity increased up to 33.9% in our group. The increase was more pronounced in men (67.1% vs. 26.6%). The WHO cut-off values underestimated the frequency of obesity in this population. Further studies are warranted for different ethnic groups.


Subject(s)
Adipose Tissue/metabolism , Body Composition/physiology , Body Mass Index , Obesity/diagnosis , Absorptiometry, Photon , Adolescent , Adult , Age Factors , Aged , Electric Impedance , Female , Humans , Male , Middle Aged , Obesity/classification , Reproducibility of Results , Sensitivity and Specificity , Sex Factors , Turkey
13.
Thyroid ; 17(4): 317-21, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17465861

ABSTRACT

OBJECTIVE: Fine-needle aspiration biopsy (FNAB) is a mandatory procedure in evaluation of thyroid nodules. However, it is sometimes perceived as a painful procedure by the patients. Efficacy of the needle-free injection of local anesthesia for reducing the pain associated with other cutaneous procedures that involve needle insertion was previously reported. In this double-blind, placebo-controlled clinical trial, we evaluated the effectiveness of a needle-free injection of lidocaine in achieving satisfactory pain control in patients undergoing FNAB of thyroid nodules. DESIGN: Patients were allocated to receive either lidocaine administered by needle-free injection system (n = 55) or placebo (isotonic saline) (n = 52) 2-3 minutes before FNAB. A series of four aspirations of each nodule was performed. The patients rated pain associated with the procedure according to a 100-mm visual analog scale (VAS), an 11-point numeric rating scale (NRS), and a four-category verbal rating scale (VRS). MAIN OUTCOME MEASURE: The two groups studied were similar with respect to age, sex, thyroid volume, nodule size, and nodule site. When the effectiveness of lidocaine was compared with that of placebo, the mean VAS score was 11.4 +/- 13.6 mm versus 38.2 +/- 35.5 mm (p < 0.0001) and the mean NRS score was 1.4 +/- 1.5 points versus 3.9 +/- 2.6 points (p < 0.0001), respectively. The absolute numbers according to VRS score in each group was also significantly different (p < 0.0001). The percentage of patients with "no pain" or "mild pain" in the lidocaine group (90.9%) was significantly higher than that in the placebo group (44.2%) (p < 0.0001). Less than 10% of the patients in lidocaine group experienced moderate pain and none experienced severe pain. No adverse treatment-related effects were observed. CONCLUSIONS: To our knowledge, this is the first study demonstrating that the needle-free delivery of lidocaine is an effective, useful, and noninvasive method of providing local anesthesia for the FNAB of thyroid nodules.


Subject(s)
Anesthesia, Local/methods , Biopsy, Fine-Needle/methods , Lidocaine/administration & dosage , Thyroid Nodule/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Pain/prevention & control
14.
J Natl Med Assoc ; 99(2): 149-52, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17366951

ABSTRACT

Recently, the term of "possible" polycystic ovary syndrome (PCOS) has been used for defining cases in which biochemical evaluations are incomplete but clinical phenotypes are suggestive of PCOS. The aim of this study was, by using Rotterdam 2003 criteria, to detect possible PCOS cases and compare their characteristics and insulin sensitivity status with confirmed PCOS subjects. One-hundred-eighteen women who admitted with complaints and symptoms suggesting PCOS were included. Insulin sensitivity status of the cases was calculated with Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Cases fulfilling Rotterdam 2003 criteria were defined as confirmed PCOS, whereas indeterminate subjects as possible PCOS. Confirmed PCOS was detected in 70 (59.3%) and possible PCOS in 48 (40.7%) cases. Confirmed PCOS was most prevalent among subjects with hirsutism and menstrual dysfunction; 32 (80.0%) vs. 8 (20%), (p=0.000). Body mass index and HOMA-IR values did not differ between groups: confirmed PCOS versus possible PCOS; 25.46+/-5.55 kg/m(2) vs. 26.75+/-7.55 kg/m(2), 3.37+/-4.12 vs. 3.21+/-2.50, (p>0.05). Family history of type-2 diabetes mellifus was similar within both groups (p>0.05). Many PCOS patients seem to be undiagnosed due to inadherence to diagnostic work-up and/or to not fulfill Rotterdam 2003 criteria. These criteria may not be sufficient to cover the entire spectrum of PCOS.


Subject(s)
Polycystic Ovary Syndrome/diagnosis , Body Mass Index , Diagnosis, Differential , Female , Hirsutism , Humans , Insulin Resistance , Menstruation Disturbances , Polycystic Ovary Syndrome/pathology , Risk Factors
15.
Clin Endocrinol (Oxf) ; 66(5): 691-4, 2007 May.
Article in English | MEDLINE | ID: mdl-17381486

ABSTRACT

OBJECTIVE: Pain is one of the few drawbacks of fine-needle aspiration biopsy (FNAB) in patients with nodular thyroid disease (NTD). Lidocaine/prilocaine cream, an eutectic mixture of local anaesthetics (EMLA), is a frequently used topical anaesthetic. Despite its well-documented efficacy for the relief of pain associated with other cutaneous procedures that involve needle insertion, the analgesic role of EMLA has not been previously reported in patients with NTD who are undergoing FNAB. The aim of this study was to determine the analgesic efficacy of EMLA for FNAB-associated pain in patients with NTD. DESIGN: Double-blind, placebo-controlled clinical trial. PATIENTS: The study was conducted at a thyroid outpatient clinic. We studied 99 patients with NTD. MEASUREMENTS: Patients with NTD were allocated to receive either 2.5 g of EMLA (n = 50) or placebo (n = 49) 60 min before ultrasonographically guided FNAB. A series of four biopsies of each nodule was performed. Patients rated pain associated with the procedure according to a 100-mm visual analogue scale (VAS), an 11-point numeric rating scale (NRS), and 4-category verbal rating scale (VRS). RESULTS: When the EMLA group was compared with the placebo group, there were no significant differences with respect to age, sex, thyroid volume, nodule size or nodule site. Significant differences were noted in the pain ratings of the two groups according to all three pain scales. When the effectiveness of EMLA was compared with that of placebo, the mean VAS score was 25.0 +/- 22.3 mm vs. 40.0 +/- 30.5 mm (P = 0.006) and the mean NRS score was 2.9 +/- 2.3 points vs. 4.0 +/- 2.6 points (P = 0.02). The absolute numbers according to VRS score in each group was also significantly different (P = 0.01). Although our sample size was small, the data suggest that FNAB-associated pain was sex-related and that women were significantly more sensitive than were men (P = 0.003 for VAS score and P = 0.001 for NRS score). No adverse effects from the use of EMLA were reported. CONCLUSIONS: To our knowledge, this is the first study demonstrating that a topical anaesthetic, EMLA, provides an effective and noninvasive analgesia during the FNAB of NTD.


Subject(s)
Anesthetics, Combined/therapeutic use , Anesthetics, Local/therapeutic use , Lidocaine/therapeutic use , Prilocaine/therapeutic use , Thyroid Nodule/pathology , Adult , Biopsy, Fine-Needle/methods , Chi-Square Distribution , Double-Blind Method , Female , Humans , Lidocaine, Prilocaine Drug Combination , Male , Middle Aged , Ointments , Pain Measurement , Sex Distribution , Thyroid Gland/diagnostic imaging , Thyroid Gland/pathology , Ultrasonography
16.
Curr Ther Res Clin Exp ; 68(4): 217-25, 2007 Jul.
Article in English | MEDLINE | ID: mdl-24683212

ABSTRACT

BACKGROUND: Strontium ranelate (SR) is a new antiosteoporotic agent with antiresorptive and bone-forming properties. The exact mechanism by which SR exerts its effects is not clearly understood. Bone resorption requires interaction between osteoblasts and osteoclasts. Osteoblasts produce a ligand for receptor activator of nuclear factor-κB (RANK). They also secrete osteoprotegerin, a decoy protein that blocks the interaction of RANK with its ligand, thereby inhibiting the differentiation and activity of osteoclasts. SR also has been associated with osteoblast proliferation and decreased osteoblast-induced osteoclast differentiation via increased osteoprotegerin messenger RNA expression in human osteoblasts. OBJECTIVE: The aim of this study was to investigate the relationship between SR treatment and serum osteoprotegerin concentration in women with post-menopausal osteoporosis (PMO). METHODS: This open, prospective study was conducted in women admitted to the outpatient endocrinology clinic of Baskent University Faculty of Medicine, Adana Medical Center, Ankara, Turkey, for the evaluation of PMO. Women with PMO who enrolled were administered elemental calcium 1000 mg/d and vitamin D 800 IU/d for 1 month before the study period. After obtaining baseline serum samples for determining osteoprotegerin concentrations, patients were assigned to the treatment or control groups at a 5:2 ratio and SR 2 g/d was administered to the treatment group. The control group continued to receive only calcium and vitamin D. Serum osteoprotegerin concentration was measured again after 3 months of treatment. RESULTS: Thirty-five women (treatment group: n = 25; mean [SD] age, 59.80 [7.38] years; control group: n = 10; mean [SD] age, 56.60 [5.06] years) enrolled in the study. A total of 32 women-24 in the treatment group and 8 in the control group-completed the study. Compared with baseline, mean [SD] serum osteoprotegerin concentration did not change significantly after 3 months in either the treatment group (4.91 [1.24] pmol/L vs 4.71 [1.19] pmol/L) or the control group (5.36 [2.82] pmol/L vs 5.10 [2.19] pmol/L). CONCLUSION: The results of this small study found that serum osteoprotegerin concentrations were not significantly changed by SR treatment for 3 months among women with PMO.

18.
Endocrine ; 29(3): 451-6, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16943584

ABSTRACT

Postprandial lipoprotein metabolism is suggested to play a role in the pathogenesis of atherosclerosis. In this study, we investigated postprandial lipemia and its relationship to cardiovascular risk factors in patients with overt and subclinical hypothyroidism. Twenty-nine female patients with TSH levels greater than 5 microIU/mL and 12 euthyroid control female subjects were included in the study. Fifteen patients had subclinical hypothyroidism and 14 had overt hypothyroidism. All subjects underwent an oral lipid tolerance test. If triglyceride levels increased by 80% or more, subjects were considered postprandial lipemia positive. Control, overt hypothyroid, and subclinical hypothyroid groups were not statistically different with respect to anthropometric measurements, fasting blood C-reactive protein, uric acid, homocysteine, glucose, insulin, lipoprotein (a), apolipoprotein B levels, and homeostasis model assessment index. Fasting triglyceride levels correlated positively with TSH levels. Postprandial lipemia frequency was higher in overt hypothyroid subjects than in the control group. The subclinical hypothyroid group did not differ from the hypothyroid group with respect to postprandial lipemia frequency. In subjects with TSH levels higher than 5 microIU/mL, PPL risk was increased sevenfold. The results of this study show that postprandial triglyceride metabolism is affected in hypothyroidism.


Subject(s)
Cardiovascular Diseases/etiology , Hypothyroidism/blood , Hypothyroidism/complications , Lipids/blood , Postprandial Period , Blood Glucose/analysis , Body Mass Index , C-Reactive Protein/analysis , Cardiovascular Diseases/epidemiology , Cholesterol/blood , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Cholesterol, VLDL/blood , Cohort Studies , Cross-Sectional Studies , Female , Homocysteine/blood , Humans , Insulin/blood , Middle Aged , Risk Factors , Thyrotropin/blood , Triglycerides/blood , Uric Acid/blood
19.
Platelets ; 17(6): 351-3, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16973494

ABSTRACT

Many studies have addressed the effects of estrogenic compounds on platelet function. Raloxifene is a selective estrogen receptor modulator (SERM), which is currently used for the treatment of postmenopausal osteoporosis. At present, there are no clinical data about the effects of raloxifene on platelet function. The purpose of this study was to determine if raloxifene at therapeutic doses affects platelet function in patients with postmenopausal osteoporosis. The effects of raloxifene on platelet function were investigated using a commercial platelet function analyzer (PFA-100) with collagen epinephrine and collagen adenosine 5'-diphosphate (ADP) cartridges. We studied platelet function of 30 patients with postmenopausal osteoporosis before and 15 days after initiation of raloxifene 60 mg/daily. Closure times did not differ significantly between samples obtained before (117.8 +/- 20.5 s) and after raloxifene therapy (106.5 +/- 25.4 s) in collagen/epinephrine cartridges (P > 0.05). There was also no statistically significant difference in mean closure times with collagen/ADP cartridges at baseline (86.2 +/- 18.5 s) and after raloxifene therapy (84.4 +/- 13.8 s) (P > 0.05). Platelet counts (278.3 +/- 72.9 vs. 262.4 +/- 56.7 109/L, P > 0.05) and mean platelet volumes (8.9 +/- 1 vs. 9.1 +/- 1 fL, P > 0.05) were not different before and after raloxifene therapy. Although estrogen related compounds do affect platelet function, there is suggestive data in our study that raloxifene in therapeutic dose exhibit no effect on platelet function in patients with postmenopausal osteoporosis.


Subject(s)
Blood Platelets/drug effects , Osteoporosis, Postmenopausal/blood , Raloxifene Hydrochloride/adverse effects , Selective Estrogen Receptor Modulators/adverse effects , Aged , Female , Humans , Middle Aged , Osteoporosis, Postmenopausal/drug therapy , Platelet Function Tests , Postmenopause/blood , Postmenopause/drug effects , Prospective Studies , Statistics, Nonparametric
20.
J Natl Med Assoc ; 98(4): 655-7, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16623082

ABSTRACT

Chylomicronemia syndrome is a rare disorder characterized by the presence of chylomicrons in the fasting state. An acute and potentially life-threatening complication of chyiomicronemia syndrome is severe acute pancreatitis. We report a case of a 24-year-old primigravida with severe hypertriglyceridemia-induced pancreatitis. We reviewed the clinical course and treatment of hypertriglyceridemia-induced pancreatitis. She was admitted in the 37th week of gestation with severe abdominal pain, which was radiating to the back, and having uterine contractions. Cesarean delivery was performed under spinal anesthesia, and a healthy male infant was born. Intraoperative findings included milky peritoneal fluid collection. Elevated pancreatic enzymes with significant hypertriglyceridemia (10,092 mg/dL) suggesting acute pancreatitis were also found on chemical analysis. The diagnosis of acute pancreatitis was confirmed by computed tomography scan. Treatment with continuous intravenous insulin--glucose, cessation of oral intake, and nasogastric decompression--dramatically decreased the triglyceride levels to 608 mg/dL within five days. She was discharged as symptom free with strict dietary intervention after 10 days. Intravenous insulin is a low-cost and effective alternative treatment in hypertriglyceridemia-induced pancreatitis during pregnancy. To our knowledge, such a high triglyceride level has not previously been reported in pregnancy.


Subject(s)
Hypertriglyceridemia/complications , Pancreatitis/etiology , Pregnancy Complications , Acute Disease , Adult , Cesarean Section , Cholesterol/blood , Female , Glucose/administration & dosage , Glucose/therapeutic use , Humans , Hypertriglyceridemia/diet therapy , Infusions, Intravenous , Insulin/administration & dosage , Insulin/therapeutic use , Pancreatitis/blood , Pancreatitis/drug therapy , Pregnancy , Pregnancy Complications/surgery , Pregnancy Trimester, Third , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...